Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335530 | 0.76 | DHODH (0.41) | PPARGNR1H4ACLYTAS1R3TAS1R1 | |
| SCHEMBL827293 | 0.76 | LMNA (0.41) | KDRKCNMA1BRAFMEN1KMT2A | |
| SCHEMBL2858561 | 0.75 | BRAF (0.55) | KDRACLYTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2853206 | 0.73 | BRAF (0.62) | KDRBRAFRAB9AIKBKBRAF1 | |
| SCHEMBL2193812 | 0.73 | PNLIP (0.46) | KDR | |
| SCHEMBL15139576 | 0.73 | BRAF (0.53) | KDRBRAFIKBKBRAF1ERBB2 | |
| SCHEMBL823625 | 0.72 | BRAF (0.52) | KDRBRAFIKBKBRAF1ERBB2 | |
| SCHEMBL826478 | 0.71 | CTSS (0.36) | KDRBRAF | |
| SCHEMBL825860 | 0.71 | TSHR (0.49) | KDRMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL29286681 | 0.71 | PTGS1 (0.52) | TMPRSS4KCNMA1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2358689-A1 | Benzothiazole derivatives as anticancer agents | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 1130/4885PPARG 1627/4885NR1H4 3107/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 1130/4885PPARG 1627/4885NR1H4 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.